Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet: Results of a prospective randomized controlled study

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Forni Ogna, Valentina ^a   Pruijm, Menno ^a   Zweiacker, Carole ^a   Wuerzner, Grégoire ^a   Tousset, Eric ^b   Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b AARDEX Group Ltd   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CINACALCET; CALCIMIMETIC AGENT; NAPHTHALENE DERIVATIVE;

ADULT; ARTICLE; CALCIUM METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOCALCEMIA; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; OPEN STUDY; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SAFETY; PRESCRIPTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; ADVERSE DRUG REACTION; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DRUG MONITORING; EPIDEMIOLOGY; METHODOLOGY; MIDDLE AGED; PREVALENCE; RISK FACTOR; STATISTICS; SWITZERLAND; TREATMENT OUTCOME; UTILIZATION REVIEW; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; PROCEDURES; STATISTICS AND NUMERICAL DATA; UTILIZATION;

CALCIMIMETIC AGENTS; CAUSALITY; COMORBIDITY; DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NAPHTHALENES; PREVALENCE; RISK FACTORS; SWITZERLAND; TREATMENT OUTCOME;

EID: 84881523217     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/104892     Document Type: Article

References (19)

1. Loghman-Adham M., Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. American Journal of Managed Care 2003 9 2 155 171 2-s2.0-0037291454 (Pubitemid 36292404)
2. Leggat J. E. Jr., Adherence with dialysis: a focus on mortality risk. Seminars in Dialysis 2005 18 2 137 141 2-s2.0-17144382040 10.1111/j.1525-139X. 2005.18212.x (Pubitemid 40522082)
3. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. Journal of the American Society of Nephrology 2001 12 10 2131 2138 2-s2.0-0034836578 (Pubitemid 32880350)
4. Leggat J. E. Jr., Orzol S. M., Hulbert-Shearon T. E., Golper T. A., Jones C. A., Held P. J., Port F. K., Noncompliance in hemodialysis: predictors and survival analysis. American Journal of Kidney Diseases 1998 32 1 139 145 2-s2.0-0031808079 (Pubitemid 28311882)
5. Block G. A., Hulbert-Shearon T. E., Levin N. W., Port F. K., Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. American Journal of Kidney Diseases 1998 31 4 607 617 2-s2.0-0031920748
6. Saran R., Bragg-Gresham J. L., Rayner H. C., Goodkin D. A., Keen M. L., Van Dijk P. C., Kurokawa K., Piera L., Saito A., Fukuhara S., Young E. W., Held P. J., Port F. K., Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney International 2003 64 1 254 262 2-s2.0-12444310126 10.1046/j.1523-1755.2003.00064.x (Pubitemid 36714179)
7. Curtin R. B., Svarstad B. L., Keller T. H., Hemodialysis patients' noncompliance with oral medications. American Nephrology Nurses Association Journal 1999 26 3 307 335 2-s2.0-0033138427
8. Claxton A. J., Cramer J., Pierce C., A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics 2001 23 8 1296 1310 2-s2.0-0034871011 10.1016/S0149-2918(01)80109-0 (Pubitemid 32804122)
9. Block G. A., Martin K. J., de Francisco A. L. M., Turner S. A., Avram M. M., Suranyi M. G., Hercz G., Cunningham J., Abu-Alfa A. K., Messa P., Coyne D. W., Locatelli F., Cohen R. M., Evenepoel P., Moe S. M., Fournier A., Braun J., McCary L. C., Zani V. J., Olson K. A., Drüeke T. B., Goodman W. G., Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. The New England Journal of Medicine 2004 350 15 1516 1525 2-s2.0-11144353767 10.1056/NEJMoa031633 (Pubitemid 38477776)
10. Lindberg J. S., Culleton B., Wong G., Borah M. F., Clark R. V., Shapiro W. B., Roger S. D., Husserl F. E., Klassen P. S., Guo M. D., Albizem M. B., Coburn J. W., Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Journal of the American Society of Nephrology 2005 16 3 800 807 2-s2.0-20544460709 10.1681/ASN.2004060512 (Pubitemid 41725117)
11. Lee A., Song X., Khan I., Belozeroff V., Goodman W., Fulcher N., Diakun D., Association of cinacalcet adherence and costs in patients on dialysis. Journal of Medical Economics 2011 14 6 798 804 2-s2.0-81255165656 10.3111/13696998.2011.627404
12. Burnier M., Santschi V., Favrat B., Brunner H. R., Monitoring compliance in resistant hypertension: an important step in patient management. Journal of Hypertension 2003 21 2 S37 S42 2-s2.0-0041866608 (Pubitemid 36900681)
13. Pruijm M., Teta D., Halabi G., Wuerzner G., Santschi V., Burnier M., Improvement in secondary hyperparathyroidism due to drug adherence monitoring in dialysis patients. Clinical Nephrology 2009 72 3 199 205 2-s2.0-70350160267
14. Vrijens B., Vincze G., Kristanto P., Urquhart J., Burnier M., Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. British Medical Journal 2008 336 7653 1114 1117 2-s2.0-44349111871 10.1136/bmj.39553.670231.25 (Pubitemid 351731741)
15. Bovet P., Burnier M., Madeleine G., Waeber B., Paccaud F., Monitoring one-year compliance to antihypertension medication in the Seychelles. Bulletin of the World Health Organization 2002 80 1 33 39 2-s2.0-0036175810 (Pubitemid 34151506)
16. Goodman W. G., Hladik G. A., Turner S. A., Blaisdell P. W., Goodkin D. A., Liu W., Barri Y. M., Cohen R. M., Coburn J. W., The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. Journal of the American Society of Nephrology 2002 13 4 1017 1024 2-s2.0-0036208986 (Pubitemid 34274098)
17. Gilbert J. R., Evans C. E., Haynes R. B., Tugwell P., Predicting compliance with a regimen of digoxin therapy in family practice. Canadian Medical Association journal 1980 123 2 119 122 2-s2.0-0019328912 (Pubitemid 10086287)
18. Paes A. H. P., Bakker A., Soe-Agnie C. J., Impact of dosage frequency on patient compliance. Diabetes Care 1997 20 10 1512 1517 2-s2.0-0030823120 (Pubitemid 27415025)
19. B. Vrijens, A. Belmans, K.Matthys et al., "Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin," Pharmacoepidemiology and Drug Safety, vol. 15, no. 2, pp. 115-121, 2006.